4 Heathcare Stock Stories for Investors Not To Miss
Amgen (NASDAQ:AMGN): Closing price $84.32
On Wednesday, Amgen announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial, which was begun in 2006. A total number of 2,278 patients suffering from symptomatic systolic heart failure and anemia (hemoglobin levels ranging from 9.0-12.0 g/dL) were randomized to receive either treatment with Aranesp to reach a target hemoglobin of a minimum of 13.0 g/dL (not to exceed 14.5 g/dL), or placebo. The evaluation failed to meet its primary endpoint of reducing the composite endpoint of time to death from any cause or first hospital admission for worsening heart failure.